Francesca Mazzoni

2.8k total citations
63 papers, 821 citations indexed

About

Francesca Mazzoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Francesca Mazzoni has authored 63 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Francesca Mazzoni's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (21 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Francesca Mazzoni is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (21 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Francesca Mazzoni collaborates with scholars based in Italy, United States and United Kingdom. Francesca Mazzoni's co-authors include Lorenzo Antonuzzo, Francesco Di Costanzo, Daniele Lavacchi, Serena Pillozzi, Enrico Caliman, Giuseppe Giaccone, Sara Fancelli, Marcello Tiseo, Camilla Comin and Laura Doni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Francesca Mazzoni

60 papers receiving 803 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesca Mazzoni Italy	18	568	470	178	160	74	63	821
Dengfeng Ren China	11	535 0.9×	346 0.7×	180 1.0×	149 0.9×	71 1.0×	47	825
Naoki Furuya Japan	16	510 0.9×	590 1.3×	181 1.0×	126 0.8×	47 0.6×	89	827
Sven Gogov Switzerland	12	351 0.6×	409 0.9×	294 1.7×	145 0.9×	56 0.8×	25	804
W. Thomas Purcell United States	16	534 0.9×	518 1.1×	244 1.4×	184 1.1×	59 0.8×	40	935
Naoko Miura Japan	17	459 0.8×	514 1.1×	224 1.3×	125 0.8×	42 0.6×	62	919
Caio Max S. Rocha Lima United States	14	537 0.9×	253 0.5×	204 1.1×	114 0.7×	156 2.1×	39	735
Fernando C. Santini United States	13	685 1.2×	464 1.0×	211 1.2×	143 0.9×	73 1.0×	34	958
Raffaele Costanzo Italy	16	563 1.0×	368 0.8×	277 1.6×	147 0.9×	194 2.6×	53	899
Sandhya Srinivas United States	9	479 0.8×	396 0.8×	250 1.4×	199 1.2×	23 0.3×	18	748
Sasja F. Mulder Netherlands	12	253 0.4×	340 0.7×	265 1.5×	130 0.8×	54 0.7×	38	669

Countries citing papers authored by Francesca Mazzoni

Since Specialization

Citations

This map shows the geographic impact of Francesca Mazzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Mazzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Mazzoni more than expected).

Fields of papers citing papers by Francesca Mazzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Mazzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Mazzoni. The network helps show where Francesca Mazzoni may publish in the future.

Co-authorship network of co-authors of Francesca Mazzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Mazzoni. A scholar is included among the top collaborators of Francesca Mazzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Mazzoni. Francesca Mazzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marinis, Filippo de, Andrea Ardizzoni, Ilaria Attili, et al.. (2025). Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting. Current Oncology. 32(2). 110–110. 2 indexed citations

Salvati, Lorenzo, et al.. (2024). Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report. Swiss Medical Weekly. 154(3). 3513–3513.

Camerini, Andrea, Francesca Mazzoni, Vieri Scotti, et al.. (2024). Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 13(13). 3642–3642. 3 indexed citations

Giommoni, Elisa, Serena Pillozzi, Enrico Caliman, et al.. (2023). Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.. Journal of Clinical Oncology. 41(16_suppl). e21144–e21144. 1 indexed citations

Cameli, Paolo, Paola Faverio, Stefania Marsili, et al.. (2022). Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. Life. 12(8). 1149–1149. 4 indexed citations

Caliman, Enrico, Francesca Mazzoni, Sara Fancelli, et al.. (2022). Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer. Current Cancer Drug Targets. 25(1). 64–71. 5 indexed citations

Andrini, Elisa, Giuseppe Lamberti, Francesca Mazzoni, et al.. (2022). A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and Rationale. Future Oncology. 18(7). 771–779. 6 indexed citations

Caliman, Enrico, Sara Fancelli, Francesca Mazzoni, et al.. (2022). Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications. 32. 100603–100603. 17 indexed citations

Pinato, David J., Daniela Ferrante, Mark Bower, et al.. (2022). Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry.. Journal of Clinical Oncology. 40(16_suppl). e18725–e18725. 2 indexed citations

10.

Landi, Lorenza, Angelo Delmonte, Andrea Bonetti, et al.. (2022). Combi-TED: A new Trial Testing Tedopi ^® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line. Future Oncology. 18(40). 4457–4464. 2 indexed citations

11.

Caliman, Enrico, Sara Fancelli, Giulia Petroni, et al.. (2022). Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification. Lung Cancer. 175. 88–100. 26 indexed citations

12.

Lavacchi, Daniele, Luca Voltolini, Camilla Comin, et al.. (2021). Primary pleural epithelioid hemangioendothelioma: case report and review of the literature. Anti-Cancer Drugs. 32(10). 1131–1137. 3 indexed citations

13.

Lavacchi, Daniele, Francesca Mazzoni, & Giuseppe Giaccone. (2019). <p>Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives</p>. Drug Design Development and Therapy. Volume 13. 3187–3198. 40 indexed citations

14.

Re, Marzia Del, Iacopo Petrini, Francesca Mazzoni, et al.. (2019). Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical Lung Cancer. 21(3). 232–237. 24 indexed citations

15.

Cappuzzo, Federico, Alessandro Morabito, Nicola Normanno, et al.. (2016). Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer. 99. 31–37. 30 indexed citations

16.

Chiari, Rita, Fiamma Buttitta, Daniela Iacono, et al.. (2014). Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer. 15(6). 470–474. 12 indexed citations

17.

Mazzoni, Francesca, Fabiana Letizia Cecere, Luca Boni, et al.. (2013). Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer. 82(2). 288–293. 30 indexed citations

18.

Santi, Raffaella, Daniela Massi, Francesca Mazzoni, Lorenzo Antonuzzo, & Camilla Comin. (2008). Skin metastasis from typical carcinoid tumor of the lung. Journal of Cutaneous Pathology. 35(4). 418–422. 11 indexed citations

19.

Costanzo, Francesco Di, Silvia Gasperoni, Paola Papaldo, et al.. (2005). Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Annals of Oncology. 17(1). 79–84. 11 indexed citations

20.

Cappuzzo, Federico, Giovanni Selvaggi, Vanesa Gregorc, et al.. (2003). Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma. Cancer. 98(1). 128–134. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact